# Efficacy and Safety of PegIFN +/- FTC / TDF to Treat Chronic Hepatitis B in HIV-Coinfected Patients

> **NCT00221286** · PHASE3 · TERMINATED · sponsor: **University Hospital, Bonn** · enrollment: 2 (actual)

## Conditions studied

- Chronic Hepatitis B
- HIV Infections

## Interventions

- **DRUG:** pegylated interferon alfa-2a
- **DRUG:** tenofovir DF / emtricitabine combination therapy
- **DRUG:** pegIFN / TDF / FTC combination therapy

## Key facts

- **NCT ID:** NCT00221286
- **Lead sponsor:** University Hospital, Bonn
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-09
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Lack of accrual
- **Last updated:** 2009-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00221286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00221286, "Efficacy and Safety of PegIFN +/- FTC / TDF to Treat Chronic Hepatitis B in HIV-Coinfected Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00221286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*